Neurology & Neuropsychiatry 10 studies
Parkinson's DiseasePhase IIa
Four-blend formulation strategy targeting NF-κB, mitochondrial bioenergetics, gut-brain axis, and proteostasis. Foundation of the cross-disease repurposing strategy used in MS, ALS, and MSA.
Multiple Sclerosis (RRMS)Locked
Four PD blends repurposed for RRMS. Lead candidate MS-IMM-01 (NF-κB modulation). Phase IIa pre-registered with seven SHA-256 locked predictions before readout.
ALSDesigned
Motor neuron neurodegeneration with mitochondrial, proteostasis, and neuroinflammation axes. Repurposes PD-MITO-02 and PD-PROT-04 blends with ALS-specific dosing.
Multiple System AtrophyDesigned
Alpha-synucleinopathy with autonomic dysfunction. Cross-walk from PD pipeline with MSA-specific autonomic endpoints and CSF biomarker panel.
Dementia / Cognitive HealthDesigned
Mixed-aetiology cognitive decline targeting vascular, metabolic, and inflammatory contributors. Cognitive-battery primary, MRI volumetric secondary.
Autism (ASD) UnifiedLocked
Unified ASD + Seizure + Tourette protocol. Four convergent mechanisms: E/I imbalance, neuroinflammation, CSTC/basal ganglia, gut-brain/5-HT. Blend TRI-01.
Anxiety / StressActive
Three-phase framework: heal the foundation, restore balance, rewire & rebuild. Persona-stratified protocol across patient, caregiver, clinician, and investor views.
Concussion RecoveryDesigned
Post-injury neuroinflammation and metabolic-recovery window. Time-from-injury stratified cohort. Cognitive, balance, and inflammatory biomarker triplet.
Pain DisordersDesigned
Chronic pain spanning neuropathic, inflammatory, and central-sensitisation phenotypes. Mechanism-anchored phenotype-to-treatment mapping.
Vagus Nerve (VNS)Concept
Non-invasive vagal stimulation combined with the inflammation- and HRV-active compound stack. Closed-loop biomarker dosing.
Cardiometabolic 6 studies
HypertensionActive
22 compounds across six BP-lowering mechanisms (RAAS, calcium, vascular tone, volume, sympathetic, endothelial). 16-week mechanism-stratified protocol.
Atherosclerosis & ReversalLocked
HTN + atherosclerosis combined protocol (28 compounds, 10 mechanisms) plus the novel five-layer reversal hypothesis. PLAQUE-REVERSE trial design with imaging endpoints.
Heart FailureDesigned
Mechanism-stratified HFpEF / HFrEF protocol. Mitochondrial, fibrosis, and neurohormonal axes. NT-proBNP and 6-minute walk endpoints.
Type 2 DiabetesDesigned
Insulin-sensitisation and β-cell preservation focus. Continuous glucose monitoring primary endpoint with HbA1c secondary.
Weight LossDesigned
Metabolic-rate, appetite-axis, and adipose-tissue inflammation triplet. Designed as a comparator and adjunct to GLP-1 standard of care.
Liver DiseaseDesigned
NAFLD/NASH-focused with fibrosis-regression endpoint. Cross-walks with the atherosclerosis reversal layer-3 mechanism (mineral resorption / macrophage axis).
Immunology & Inflammation 4 studies
Rheumatoid ArthritisDesigned
Synovial inflammation, autoimmune T-cell axis, and microbiome-driven inflammation. Designed for biologic-naive and post-biologic-failure cohorts.
Relapsing PolychondritisDesigned
Rare autoimmune cartilage disorder. Cross-walks with RA mechanism stack with cartilage-specific anti-inflammatory and proteostasis modifiers.
FibromyalgiaDesigned
Central sensitisation, autonomic dysfunction, and low-grade inflammation triplet. PROMIS pain primary, HRV and inflammatory biomarker secondary.
Gum Disease (Periodontitis)Designed
Oral microbiome, systemic inflammation, and cross-disease cardiometabolic links. Local + systemic protocol with bleeding-on-probing and CRP endpoints.
Specialty 4 studies
Fertility SupportDesigned
Mitochondrial and oxidative-stress axis for oocyte and sperm quality. Pre-conception 90-day protocol with AMH and DNA-fragmentation endpoints.
LymphedemaDesigned
Post-surgical and primary lymphedema with lymphangiogenic compound stack and mechanical-decongestion synergy.
Teen AcneDesigned
Hormone, sebum-microbiome, and inflammation triplet for adolescent acne. Designed as an alternative to systemic isotretinoin for moderate cases.
Longevity & HealthspanDesigned
Six-study program covering all twelve hallmarks of aging. Biomarker-class-stratified Phase 1/2 trials in defined disease subpopulations (frailty, sarcopenia, MCI) — not "healthy aging". TROFFi-style responder enrichment.
Want the full protocol on any of these?
The abstracts above are public. Full pre-registration documents, locked predictions, blend formulations, agent-network reasoning chains, and Phase IIa trial designs are available to verified clinicians, researchers, and sponsors. We will not gate methodology — we will share it under MNDA with anyone who can use it.
Contact management →